These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 20543597)

  • 41. Human hyper-IgE syndrome: singular or plural?
    Zhang Q; Boisson B; Béziat V; Puel A; Casanova JL
    Mamm Genome; 2018 Aug; 29(7-8):603-617. PubMed ID: 30094507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyper-IgE syndrome.
    Minegishi Y
    Curr Opin Immunol; 2009 Oct; 21(5):487-92. PubMed ID: 19717292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection.
    Maggi E; Giudizi MG; Biagiotti R; Annunziato F; Manetti R; Piccinni MP; Parronchi P; Sampognaro S; Giannarini L; Zuccati G; Romagnani S
    J Exp Med; 1994 Aug; 180(2):489-95. PubMed ID: 8046328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The hyper-IgE syndromes.
    Freeman AF; Holland SM
    Immunol Allergy Clin North Am; 2008 May; 28(2):277-91, viii. PubMed ID: 18424333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hyper-IgE recurrent infection syndrome: pathogenesis, diagnosis and therapeutic management].
    Guisado Vasco P; Fraile Rodríguez G; Arechaga Uriarte S
    Rev Clin Esp; 2011 Nov; 211(10):520-6. PubMed ID: 21700278
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Danion F; Aimanianda V; Bayry J; Duréault A; Wong SSW; Bougnoux ME; Tcherakian C; Alyanakian MA; Guegan H; Puel A; Picard C; Lortholary O; Lanternier F; Latgé JP
    Front Immunol; 2020; 11():38. PubMed ID: 32047500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3.
    Paulson ML; Freeman AF; Holland SM
    Curr Opin Allergy Clin Immunol; 2008 Dec; 8(6):527-33. PubMed ID: 18978467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hyper IgE syndrome associated with novel and recurrent STAT3 mutations: Two case reports.
    Deng Y; Li T; Xie X; Xia D; Ding L; Xiang H; Ma JJ; Li W
    Medicine (Baltimore); 2019 Feb; 98(6):e14003. PubMed ID: 30732127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A set of clinical and laboratory markers differentiates hyper-IgE syndrome from severe atopic dermatitis.
    Kasap N; Celik V; Isik S; Cennetoglu P; Kiykim A; Eltan SB; Nain E; Ogulur I; Baser D; Akkelle E; Celiksoy MH; Kocamis B; Cipe FE; Yucelten AD; Karakoc-Aydiner E; Ozen A; Baris S
    Clin Immunol; 2021 Feb; 223():108645. PubMed ID: 33301882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. STAT3 Hyper-IgE Syndrome-an Update and Unanswered Questions.
    Tsilifis C; Freeman AF; Gennery AR
    J Clin Immunol; 2021 Jul; 41(5):864-880. PubMed ID: 33932191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SH2-domain mutations in STAT3 in hyper-IgE syndrome patients result in impairment of IL-10 function.
    Giacomelli M; Tamassia N; Moratto D; Bertolini P; Ricci G; Bertulli C; Plebani A; Cassatella M; Bazzoni F; Badolato R
    Eur J Immunol; 2011 Oct; 41(10):3075-84. PubMed ID: 21792878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expansion of CCR4+ activated T cells is associated with memory B cell reduction in DOCK8-deficient patients.
    Caracciolo S; Moratto D; Giacomelli M; Negri S; Lougaris V; Porta F; Pajno G; Salpietro A; Montin D; Dinwiddie DL; Kingsmore SF; Plebani A; Badolato R
    Clin Immunol; 2014; 152(1-2):164-70. PubMed ID: 24674883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hyper-IgE syndrome, 2021 update.
    Minegishi Y
    Allergol Int; 2021 Oct; 70(4):407-414. PubMed ID: 34419355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Th17 cells, HIV and the gut mucosal barrier.
    Dandekar S; George MD; Bäumler AJ
    Curr Opin HIV AIDS; 2010 Mar; 5(2):173-8. PubMed ID: 20543596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cutaneous manifestations of Hyper IgE syndrome.
    Minegishi Y; Saito M
    Allergol Int; 2012 Jun; 61(2):191-6. PubMed ID: 22441639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hyper IgE syndromes: clinical and molecular characteristics.
    Al-Shaikhly T; Ochs HD
    Immunol Cell Biol; 2019 Apr; 97(4):368-379. PubMed ID: 30264496
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A systematic review regarding the prevalence of malignancy in patients with the hyper-IgE syndrome.
    Mohammadi T; Azizi G; Rafiemanesh H; Farahani P; Nirouei M; Tavakol M
    Clin Exp Med; 2023 Dec; 23(8):4835-4859. PubMed ID: 37924455
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.
    Renner ED; Rylaarsdam S; Anover-Sombke S; Rack AL; Reichenbach J; Carey JC; Zhu Q; Jansson AF; Barboza J; Schimke LF; Leppert MF; Getz MM; Seger RA; Hill HR; Belohradsky BH; Torgerson TR; Ochs HD
    J Allergy Clin Immunol; 2008 Jul; 122(1):181-7. PubMed ID: 18602572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Defective trained immunity in patients with STAT-1-dependent chronic mucocutaneaous candidiasis.
    Ifrim DC; Quintin J; Meerstein-Kessel L; Plantinga TS; Joosten LA; van der Meer JW; van de Veerdonk FL; Netea MG
    Clin Exp Immunol; 2015 Sep; 181(3):434-40. PubMed ID: 25880788
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome.
    Bocchini CE; Nahmod K; Katsonis P; Kim S; Kasembeli MM; Freeman A; Lichtarge O; Makedonas G; Tweardy DJ
    Blood; 2016 Dec; 128(26):3061-3072. PubMed ID: 27799162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.